References:
1. Nplate® (romiplostim) prescribing information, Amgen.
2. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from
a phase 2 study. Br J Haematol. 2016;172(2):262-273.
3. Data on file, Amgen; Clinical Study Report 20080435; 2014.
4. Data on file, Amgen; Number of patients treated with Nplate® from launch through to June 2024;
Updated 2024.
5. Data on file, Amgen; Time to Onset, biostatistical analysis; 2019.
6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv.
2019;3(23):3829-3866.
7. Rituxan® (rituximab) full Prescribing Information, Genentech.
8. Lozano ML, Mingot-Castellano ME, Perera MM, et al. Deciphering predictive factors for choice of thrombopoietin receptor
agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Sci Rep. 2019;9(1):16680.
9. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary
immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(Suppl):1-4.
10. Promacta® (eltrombopag) full Prescribing Information, Novartis.
11. Doptelet® (avatrombopag) full Prescribing
Information, Sobi.
12. Tavalisse® (fostamatinib disodium hexahydrate) full Prescribing Information, Rigel.
13. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune
thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411-423.
14. Gilani B, Cassagnol M. Biochemistry, Cytochrome P450. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January
2024. https://www.ncbi.nlm.nih.gov/books/NBK557698/.
15. Data on file, Amgen; Nplate® IQVIA LAAD 2022 and 2023 OOP Cost Analysis Medicare Commercial Combined ALL; 2024. 16. Data on file, Amgen; Nplate® -
coverage from MMIT; 2024.